

NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.

August 4, 2021

Oncolys BioPharma Inc.

Oncolys to partner with Thermo Fisher Scientific for viral vector development and GMP manufacturing of their proprietary oncolytic virus, OBP-301

Tokyo, Japan, August 4, 2021 -- Oncolys BioPharma Inc. (Head Office: Minato-ku, Tokyo; (JPX:4588), "Oncolys") announced that it has selected Thermo Fisher Scientific as a CDMO partner for GMP manufacturing of the oncolytic viral therapy, Telomelysin (OBP-301: suratadenoturev).

The uniquely engineered Telomelysin oncolytic virus is currently being evaluated in the treatment of esophageal, head and neck, hepatocellular, gastric/ gastroesophageal junction cancer.

Thermo Fisher's sites in Seneffe and Gosselies, Belgium will provide a range of services including tech transfer, process development and validation and drug substance and product manufacturing. The Belgium sites are part of the Thermo Fisher's global network of sites providing viral vector services, which include U.S. sites in Cambridge, Lexington and Plainville, Massachusetts, and Alachua, Florida. Oncolys expects that the services conducted by Thermo Fisher will contribute to advancing clinical phases and the approval process for its Telomelysin viral therapy.

###

About Oncolys BioPharma Inc.

Oncolys BioPharma Inc. (JPX:4588) develops novel cancer therapeutics and diagnostic products using gene modified viral technologies and aims to contribute to fulfill unmet medical needs for cancer and severe infectious diseases. Especially in oncology area, we utilize technology platform for oncolytic virus and develop Telomelysin and its next-generation for cancer treatment and TelomeScan for early detection of cancer and recurrence monitoring after surgery. We have established broad range of product pipeline to cover early detection of cancer, early treatment of local cancer, post-operative examination, and treatment of metastatic cancer. For more information, please visit <http://www.oncolys.com/en/>

Media Contacts:

Email: oncolys_information@oncolys.com